Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. Abstract Text:

David Duggan,Siqun L Zheng,Michele Knowlton,Debbie Benitez,Latchezar Dimitrov,Fredrik Wiklund,Christiane Robbins,Sarah D Isaacs,Yu Cheng,Ge Li,Jielin Sun,Bao-Li Chang,Leslie Marovich,Kathleen E Wiley,Katarina , Stattin,Hans-Olov Adami,Marta Gielzak,Guifang Yan,Jurga Sauvageot,Wennuan Liu,Jin Woo Kim,Eugene R Bleecker,Deborah A Meyers,Bruce J Trock,Alan W Partin,Patrick C Walsh,William B Isaacs,Henrik ,Jianfeng Xu,John D Carpten,David Duggan,Siqun L Zheng,Michele Knowlton,Debbie Benitez,Latchezar Dimitrov,Fredrik Wiklund,Christiane Robbins,Sarah D Isaacs,Yu Cheng,Ge Li,Jielin Sun,Bao-Li Chang,Leslie Marovich,Kathleen E Wiley,Katarina , Stattin,Hans-Olov Adami,Marta Gielzak,Guifang Yan,Jurga Sauvageot,Wennuan Liu,Jin Woo Kim,Eugene R Bleecker,Deborah A Meyers,Bruce J Trock,Alan W Partin,Patrick C Walsh,William B Isaacs,Henrik ,Jianfeng Xu,John D Carpten,

BACKGROUND: The consistent finding of a genetic susceptibility to prostate cancer suggests that there are germline sequence variants predisposing individuals to this disease. These variants could be useful in screening and treatment. METHODS: We performed an exploratory genome-wide association scan in 498 men with aggressive prostate cancer and 494 control subjects selected from a population-based case-control study in Sweden. We combined the results of this scan with those for aggressive prostate cancer from the publicly available Cancer Genetic Markers of Susceptibility (CGEMS) Study. Single-nucleotide polymorphisms (SNPs) that showed statistically significant associations with the risk of aggressive prostate cancer based on two-sided allele tests were tested for their association with aggressive prostate cancer in two independent study populations composed of individuals of European or African American descent using one-sided tests and the genetic model (dominant or additive) associated with the lowest value in the exploratory study. RESULTS: Among the approximately 60,000 SNPs that were common to our study and CGEMS, we identified seven that had a similar (positive or negative) and statistically significant (P<.01) association with the risk of aggressive prostate cancer in both studies. Analysis of the distribution of these SNPs among 1032 prostate cancer patients and 571 control subjects of European descent indicated that one, rs1571801, located in the DAB2IP gene, which encodes a novel Ras GTPase-activating protein and putative prostate tumor suppressor, was associated with aggressive prostate cancer (one-sided P value = .004). The association was also statistically significant in an African American study population that included 210 prostate cancer patients and 346 control subjects (one-sided P value = .02). CONCLUSION: A genetic variant in DAB2IP may be associated with the risk of aggressive prostate cancer and should be evaluated further.

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. Publishing Authors By Initials

D Duggan,SL Zheng,M Knowlton,D Benitez,L Dimitrov,F Wiklund,C Robbins,SD Isaacs,Y Cheng,G Li,J Sun,BL Chang,L Marovich,KE Wiley,K ,P Stattin,HO Adami,M Gielzak,G Yan,J Sauvageot,W Liu,JW Kim,ER Bleecker,DA Meyers,BJ Trock,AW Partin,PC Walsh,WB Isaacs,H ,J Xu,JD Carpten,D Duggan,SL Zheng,M Knowlton,D Benitez,L Dimitrov,F Wiklund,C Robbins,SD Isaacs,Y Cheng,G Li,J Sun,BL Chang,L Marovich,KE Wiley,K ,P Stattin,HO Adami,M Gielzak,G Yan,J Sauvageot,W Liu,JW Kim,ER Bleecker,DA Meyers,BJ Trock,AW Partin,PC Walsh,WB Isaacs,H ,J Xu,JD Carpten,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Journal of the National Cancer Institute

VOLUME: 99

Page Numbers: 1836-44

Journal Abbreviation: J. Natl. Cancer Inst.

ISSN: 1460-2105

DAY: 11

MONTH: 12

YEAR: 2007

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7503089

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.

AFFILIATION: Division of Genetic Basis of Human Disease, Translational Genomics Research Institute, Phoenix, AZ, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Natl Cancer Inst

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP Related Publications

• Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus.
• Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC).
• PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation.
• Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.